HGF and familial pancreatic carcinoma: Given the potential clinical benefit for addition of ficlatuzumab to cytotoxic therapy, further evaluation of HGF/c-Met pathway inhibitors may be warranted in patients with pancreatic cancer, although alternate cytotoxic backbones that do not induce additive peripheral edema may be preferable.